Trials

IMPACT clinical trials will focus on improving stem cell transplant outcomes. Some trials will focus on the treatment of a specific disease, while others will focus on the complications arising from transplant, such as Graft versus Host Disease.

An open competitive call for trial concept proposals will be made to all major UK transplant centres twice a year, and these proposals will initially be reviewed by senior members of the IMPACT Hub in collaboration with the BSBMT Clinical Trials Committee.

More information about individual trials will be added here as they are approved as IMPACT trials.

PRO-DLI: A Phase II Prospective Trial of Prophylactic Donor Lymphocyte Infusions for the Prevention of Relapse post HSCT in patients with High Risk Myeloid Malignancy

Chief Investigator: Dr Victoria Potter

COSI: An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myeldysplasia Undergoing Allogeneic Stem Cell Transplantation 

Chief Investigator: Professor Charles Craddock

ALL-RIC: A comparison of two low-intensity transplant regimens for the treatment of adults with acute lymphoblastic leukaemia (ALL)

Chief Investigator: Professor David Marks

AMADEUS: A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation

Chief Investigator: Professor Charles Craddock

MoTD: A multi-centre phase II trial of GVHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant Cyclophosphamide

Chief Investigator: Professor Ronjon Chakraverty

COVID19_BMT: A prospective non interventional study to evaluate the role of immune and inflammatory response in recipients of allogeneic haematopoietic stem cell transplantation (SCT) affected by severe COVID19 infection

Chief Investigator: Dr Giovanna Lucchini

RATinG: Risk Adapted Therapy in Acute GvHD; Investigating the use of Lenzilumab for treating high-risk acute graft versus host disease following allogenic stem cell transplantation

Chief Investigator: Dr Adrian Bloor

If you are a patient and interested in taking part in a clinical trial, please speak with your consultant who will be able to offer you further information and discuss whether it is suitable for you. A referral from your medical team would be required in order to consider you for treatment on a clinical trial.